We are guided by the healthcare needs people have today and tomorrow.
Lasting health is shaped by what happens today, tomorrow and every day after.
This understanding guides what we do. We’re a global healthcare company with more than a century of experience working to defeat serious chronic diseases, including obesity and diabetes.
Because health affects the whole person, we consider people’s bodies, minds, daily lives, relationships and communities. We use this understanding to develop science-based treatments and support that fit real life.
Our goal is simple: help people make progress they can see, feel and sustain.
Delivering meaningful change requires collective effort. We work with a wide range of collaborators to improve patient access and provide support tailored to your needs and goals.
Our US headquarters plays a critical role in the vibrancy of the life sciences industry. Here we are responsible for Corporate and Commercial Operations, Medical Affairs functions and Clinical Trials management for all Novo Nordisk US products.
Our manufacturing and research facility for RNAi therapeutics. This site specializes in operations and chemistry manufacturing and controls (CMC) for oligonucleotides and RNAi therapeutics.
This site expands our manufacturing capacity to meet current and future demand for our rare and chronic disease products. Operators and technicians work various shifts around-the-clock depending on facility and production needs.
Our greater Boston R&D hub, located in Lexington, Watertown and Cambridge, brings together the best minds in life science innovation. Here, we are building for the future, creating a distinct R&D community based on collaboration, partnerships, and cutting-edge research.
Our West Lebanon, New Hampshire site is a life-science production facility focused on continuous manufacturing to deliver products for rare bleeding disorders and growth disorders.
For more than 30 years, North Carolina has been home to Novo Nordisk’s first and largest manufacturing presence in the US. With a facility located in Durham, two additional sites in Clayton, and currently undergoing a $4.1 billion expansion, our teams operate continuously to produce diabetes and obesity medications serving millions of patients.
Our newly acquired manufacturing facility in Petersburg is focused on increasing development and production of future Novo Nordisk products.
